MedTrace Logo

Utility Study of Primovist-MRI on HCC Staging

NCT01764438 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 174

Last updated 2013-01-09

No results posted yet for this study

Summary

Gadoxetic acid (Gd-EOB-DTPA, Primovist)-enhanced MRI can affect on BCLC staging during the initial staging workups of definite HCC patients with very early or early stage disease, but with no suspicious intrahepatic HCC lesions by liver dynamic CT.

Conditions

Interventions

PROCEDURE

Primovist-enhanced MRI

Performance of Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious intrahepatic HCC lesions by liver dynamic CT.

Sponsors & Collaborators

  • Inha University Hospital

    lead OTHER

Principal Investigators

  • Jin-Woo Lee, M.D. · Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon, Repubulic of Korea

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01764438 on ClinicalTrials.gov